Merck KGaA Agrees to Buy Silence Therapeutics for $1.3 Billion

Has Merck KGaA completed the Silence Therapeutics acquisition?

No. The agreement was announced on October 19, 2026, and completion is expected in the first quarter of 2027 through a UK scheme of arrangement.

Orbitrum Investor Impact

How much is Merck paying for Silence Therapeutics?

Merck is offering $20 per American depositary share in an all-cash transaction valued at approximately $1.3 billion. The offer represents a 130% premium to Silence Therapeutics' last closing price before the announcement.

Why does the acquisition matter for Merck KGaA investors?

The acquisition expands Merck's gene-silencing capabilities and adds a broader small interfering RNA (siRNA) research platform and clinical pipeline. The investment case depends on advancing these drug candidates and ultimately generating commercially successful treatments; the announcement does not establish future revenue or profit.

What drug candidates does Merck gain from Silence Therapeutics?

The pipeline includes divesiran, expected to enter late-stage testing for polycythemia vera, and zerlasiran, which targets elevated lipoprotein(a), a blood protein associated with cardiovascular disease. Silence is also developing earlier-stage treatments for high cholesterol, obesity and immune-related diseases.

Could the acquisition affect Merck KGaA stock?

The deal could strengthen Merck's long-term growth prospects if its acquired drug candidates and technology produce successful medicines. The $1.3 billion purchase price creates an investment commitment, while the eventual financial return depends on development outcomes, regulatory approvals, commercialization and integration.

What should investors watch next?

Investors should watch for completion of the transaction, expected in the first quarter of 2027, and subsequent clinical-development milestones for the acquired pipeline. The announcement does not establish when the drug candidates will reach market or how much revenue they could generate.